Cargando…

A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis of cardiovascular disorders including hypertension and is one of the most important targets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model integrating this hormone circulation system a...

Descripción completa

Detalles Bibliográficos
Autores principales: Claassen, Karina, Willmann, Stefan, Eissing, Thomas, Preusser, Tobias, Block, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567458/
https://www.ncbi.nlm.nih.gov/pubmed/23404365
http://dx.doi.org/10.3389/fphys.2013.00004
_version_ 1782258706527813632
author Claassen, Karina
Willmann, Stefan
Eissing, Thomas
Preusser, Tobias
Block, Michael
author_facet Claassen, Karina
Willmann, Stefan
Eissing, Thomas
Preusser, Tobias
Block, Michael
author_sort Claassen, Karina
collection PubMed
description The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis of cardiovascular disorders including hypertension and is one of the most important targets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model integrating this hormone circulation system and its inhibition can be used to explore the influence of drugs that interfere with this system, and thus to improve the understanding of interactions between drugs and the target system. In this study, we describe the development of a mechanistic RAAS model and exemplify drug action by a simulation of enalapril administration. Enalapril and its metabolite enalaprilat are potent inhibitors of the angiotensin-converting-enzyme (ACE). To this end, a coupled dynamic parent-metabolite PBPK model was developed and linked with the RAAS model that consists of seven coupled PBPK models for aldosterone, ACE, angiotensin 1, angiotensin 2, angiotensin 2 receptor type 1, renin, and prorenin. The results indicate that the model represents the interactions in the RAAS in response to the pharmacokinetics (PK) and pharmacodynamics (PD) of enalapril and enalaprilat in an accurate manner. The full set of RAAS-hormone profiles and interactions are consistently described at pre- and post-administration steady state as well as during their dynamic transition and show a good agreement with literature data. The model allows a simultaneous representation of the parent-metabolite conversion to the active form as well as the effect of the drug on the hormone levels, offering a detailed mechanistic insight into the hormone cascade and its inhibition. This model constitutes a first major step to establish a PBPK-PD-model including the PK and the mode of action (MoA) of a drug acting on a dynamic RAAS that can be further used to link to clinical endpoints such as blood pressure.
format Online
Article
Text
id pubmed-3567458
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-35674582013-02-12 A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System Claassen, Karina Willmann, Stefan Eissing, Thomas Preusser, Tobias Block, Michael Front Physiol Physiology The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis of cardiovascular disorders including hypertension and is one of the most important targets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model integrating this hormone circulation system and its inhibition can be used to explore the influence of drugs that interfere with this system, and thus to improve the understanding of interactions between drugs and the target system. In this study, we describe the development of a mechanistic RAAS model and exemplify drug action by a simulation of enalapril administration. Enalapril and its metabolite enalaprilat are potent inhibitors of the angiotensin-converting-enzyme (ACE). To this end, a coupled dynamic parent-metabolite PBPK model was developed and linked with the RAAS model that consists of seven coupled PBPK models for aldosterone, ACE, angiotensin 1, angiotensin 2, angiotensin 2 receptor type 1, renin, and prorenin. The results indicate that the model represents the interactions in the RAAS in response to the pharmacokinetics (PK) and pharmacodynamics (PD) of enalapril and enalaprilat in an accurate manner. The full set of RAAS-hormone profiles and interactions are consistently described at pre- and post-administration steady state as well as during their dynamic transition and show a good agreement with literature data. The model allows a simultaneous representation of the parent-metabolite conversion to the active form as well as the effect of the drug on the hormone levels, offering a detailed mechanistic insight into the hormone cascade and its inhibition. This model constitutes a first major step to establish a PBPK-PD-model including the PK and the mode of action (MoA) of a drug acting on a dynamic RAAS that can be further used to link to clinical endpoints such as blood pressure. Frontiers Media S.A. 2013-02-08 /pmc/articles/PMC3567458/ /pubmed/23404365 http://dx.doi.org/10.3389/fphys.2013.00004 Text en Copyright © 2013 Claassen, Willmann, Eissing, Preusser and Block. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Physiology
Claassen, Karina
Willmann, Stefan
Eissing, Thomas
Preusser, Tobias
Block, Michael
A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
title A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
title_full A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
title_fullStr A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
title_full_unstemmed A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
title_short A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
title_sort detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine renin-angiotensin-aldosterone system
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567458/
https://www.ncbi.nlm.nih.gov/pubmed/23404365
http://dx.doi.org/10.3389/fphys.2013.00004
work_keys_str_mv AT claassenkarina adetailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT willmannstefan adetailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT eissingthomas adetailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT preussertobias adetailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT blockmichael adetailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT claassenkarina detailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT willmannstefan detailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT eissingthomas detailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT preussertobias detailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem
AT blockmichael detailedphysiologicallybasedmodeltosimulatethepharmacokineticsandhormonalpharmacodynamicsofenalaprilonthecirculatingendocrinereninangiotensinaldosteronesystem